Orexigen Takeda deal

Orexigen jumped over 25% in premarket trading after announcing an exclusive partnership agreement potentially worth over $1 billion with Japan's Takeda Pharmaceutical to develop and commercialize Contrave, Orexigen's promising obesity drug.